J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
The company might have blown Enliven out of the water.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Pfizer reveals the discontinuation of PF-08046044.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
Studies presented at ASH show this to be true only up to a point.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
